Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Trigon Agri A/S: Update on debt to equity swap to its bondholders

As communicated in the 23 March 2016 announcement “EUR 1.5 million released to Trigon Agri A/S – Conditional upon a partial debt to equity swap to its bondholders”, Trigon Agri A/S (“Trigon”) has entered into an agreement with a committee of holders (the “Holders’ Committee”) under its SEK 350,000,000 11% bonds with ISIN SE0004019008 (the “Bond Loan”). As is set out in the announcement, Trigon is obliged to repay EUR 1.5 million to a blocked account if all applicable conditions for the debt to equity swap are not fulfilled by 17 May 2016. As certain administrative and technical aspects

Jan Johansson new CFO at Scandic

Jan Johansson has been appointed as the new CFO at Scandic Hotels Group. Jan is 53 years old and has many years of experience in the role of CFO, including from the listed companies Eniro and Nobia. Since 2011, he has been CFO at Apoteket, a state-owned pharmaceutical retailer. -  Jan has vast experience from his role as CFO at several listed companies. His work on the transformation of Apoteket into a competitive enterprise has further strengthened his leadership. I extend a warm welcome to Scandic to Jan, says Frank Fiskers, President & CEO of Scandic Hotels Group. -  With its

Moody's assigns (P)Ba2 rating to Hoist Kredit’s EMTN programme. The rating together with Hoist's Ba2 issuer rating are also under review for upgrade

On May 16, Moody Investor’s Service (Moody’s) assigned (P)Ba2 long-term senior unsecured rating to the forthcoming EUR 750 million EMTN programme (the “Programme”) of Hoist Kredit AB (publ) (“Hoist”).Moody's has also placed Hoist's long-term issuer rating Ba2 and the Programme rating (P)Ba2 under review for upgrade. An upgrade is expected following the settlement of a first issue under the Programme.The review for upgrade of Hoist's long-term issuer and long-term senior, unsecured Programme ratings to Ba1 and (P)Ba1 respectively, is supported by Moody's expectation that the change in

Conference call regarding information on the offer made to Vivoline’s shareholders

Invitation to attend XVIVO Perfusion’s conference call regarding information on the offer made to Vivoline’s shareholders. The presentation will be held in Swedish.This press release may not, directly nor indirectly, be distributed in or to, Australia, Hong Kong, Japan, Canada, New Zeeland, South Africa or the U.S or in any other country where making of the Offer, distribution of this press release or acceptance of the Offer would be contrary to applicable laws or rules or would require further offering documentation or registration or any other measures in addition to what is required by

Ongoing US study shows that IdeS allows for transplantation of highly sensitized patients

An initial evaluation of the ongoing US study with IdeS at Cedars Sinai Medical Center shows that IdeS completely eliminates donor specific antibodies and allows for kidney transplantation in all sensitized patients. These results are for four patients that were included in the US study as of January 2016. As of today 10 patients have been treated and subsequently transplanted. Initial results from the study will be presented by Professor Stanley Jordan, the study’s principal investigator, at the 2016 American Transplant Congress (ATC) in Boston on June 14 at 6:00 pm.The ongoing Phase II

A1M Pharma initiates research collaboration with global leader CSL Behring for combination treatment with A1M and plasma proteins

A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential for combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin. This collaboration strengthens A1M Pharma’s position in the use of A1M for the treatment of life-threatening diseases with therapies that are based on naturally occurring substances.Many proteins in the human body contribute to immunoprotection against disease processes. Their different activities often act together to address

Interim report 1 January - 31 March

First quarter 2016 for the Group compared to 2015 » Group net sales increased by 81% to SEK 411,834 (227,011).» Other operating income amounted to SEK 565,286 (1,456,375).» Income after financial items amounted to SEK –11,696,747 (–7,533,225).» Earnings per share (weighted average) amounted to SEK –0.73 (–0.95).» Equity per share amounted to SEK 6.16 (3.94).» Equity ratio amounted to 94.1% (86.4).   Significant events during the first quarter » Episurf Medical receives CE mark for its fifth product, Epioscopy® Damage Assessment Tool.» Episurf Medical has been granted

Atrophic gastritis and vitamin B12 deficiency remain often undetected in elderly people – early diagnosis is important to prevent complications

Biohit Oyj Press Release May 17, 2016 at 09:30 am local time (EEST) Early diagnosis of atrophic gastritis and vitamin B12 deficiency in elderly people is important in order to prevent, for instance, irreversible neurological complications. Atrophic gastritis is caused by Helicobacter pylori infection or autoimmune disease. Atrophic gastritis, related i.a. to risk for gastric cancer, can be one important reason leading to vitamin B12 deficiency. A majority of B12 vitamin deficient cases in Estonia but less than 25% in Finland remains undiagnosed. This is evident in a study comparing

NICOCCINO FOCUS ON ACHIEVING A DRUG CLASSIFICATION AND IMPLEMENTS A NEW STRATEGY

In March 2016 Nicoccino Holding developed a new strategic direction with an increased focus on achieving a drug classification for the company’s alternative nicotine product – NicoccinoTM– in order to position the product as a smoking cessation.This new direction has resulted in a revised set of strategies as well an amended business model and Vision/Mission for the company that can be seen below. The strategy is to create a product platform that can be used by partners who wish to establish themselves in the market of Nicotine Replacement Therapy (NRT) or want to expand their existing

POSITIVE BENRALIZUMAB RESULTS IN SEVERE ASTHMA

ASTRAZENECA ANNOUNCES POSITIVE RESULTS FROM BENRALIZUMABPHASE III PROGRAMME IN SEVERE ASTHMA Benralizumab first AstraZeneca respiratory biologic to complete Phase III 17 May 2016 AstraZeneca today announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials (SIROCCO and CALIMA), demonstrating significant reductions in the annual asthma exacerbation rate compared to placebo. Sean Bohen, Executive Vice President, Global Medicines Development and

GROWTH WITH HIGH PROFITABILITY

PRECISE BIOMETRICS AB (PUBL), CORPORATE IDENTITY NO. 556545-6596 INTERIM REPORT FOR THE FIRST QUARTER 2016· Consolidated net sales increased to SEK 24.2 (4.5) million. · EBITDA increased to SEK 8.2 (-6.4) million. · Profit after tax increased to SEK 6.3 (-8.8) million. · Earnings per share for the period increased to SEK 0.02 (-0.03). · Cash and cash equivalents were SEK 58.6 (50.7) million. SIGNIFICANT EVENTS IN THE FIRST QUARTER · Precise BioMatch Mobile was integrated in over 25 smartphones. · Licensing agreements were signed with sensor manufacturers Chipone

Fredrik Strand discontinues as President and CEO of Caverion

Caverion Corporation Stock exchange release May 17, 2016 at 9:00 a.m. EESTFredrik Strand discontinues as President and CEO of Caverion Caverion Corporation and its President and CEO Fredrik Strand have jointly agreed that Fredrik Strand will discontinue his duties as President and CEO of Caverion Corporation immediately. Fredrik Strand has served as President and CEO of Caverion Corporation since April 2014. The Board of Directors of Caverion Corporation will immediately initiate the application process for a new President and CEO. Vice President, Group Strategy and M&A Sakari

Period from January 2016 to March 2016

2016 FIRST QUARTER (Jan-Mar) · Operating loss KSEK -3,551 (-2,644)  · Loss per share SEK -0.18 (-0.33)IMPORTANT EVENTS DURING THE PERIOD · In March Peptonic Medical received approval to start the planned clinical Phase 2b study from the Swedish Medical Products Agency. Previously Peptonic had received approval from the Ethical Vetting Board. · The Formulation patent has been approved also in China.Earlier it has been approved i.a. in Europe and the US. IMPORTANT EVENTS AFTER THE END OF THE PERIOD · The Nomination Committee will propose to the Annual General Meeting

Nearly all retail spaces at Lauttis Shopping Centre leased out

YIT CORPORATION Press Release, May 17, 2016 at 9:00 a.m.Over 90% of the retail space at the Lauttis Shopping Centre, scheduled to open in late 2016, has already been leased out. The tenants at the new shopping centre include K-Supermarket, S-Market, Alko, Pharmacy, Nordea Bank, Instrumentarium, Silmäasema opticians, Salon Pepe Åhman, Life health food shop, Karkkitori pick’n’mix, Kukkakaari florist, Erkkeri real estate agent, and R-kioski. The shopping centre will also house a number of quality restaurants and cafés, such as Pizzarium, Ahorita, Hanko Sushi, and Fazer Bakery, Espresso House,

Bonava sells rental units in Linköping and Karlstad

NCC’s subsidiary Bonava (formerly NCC Housing) is selling a total of 352 newly developed Nordic Swan ecolabelled rental units in Linköping and Karlstad to the housing company Willhem. The sale is being carried out in the form of a company transaction at a value of SEK 595 M.“We are delighted to be developing new Nordic Swan ecolabelled rental units in Karlstad and Linköping. Our goal is to deliver high-quality residential environments with sustainable housing with various forms of tenure. Rental units are an important and growing part of our business,” says Joachim Hallengren, CEO of Bonava.

Read original

Bulletin from annual general meeting of SciBase Holding AB (publ) on 16 May 2016

At the annual general meeting of SciBase Holding AB (publ) on 16 May 2016 in Stockholm the shareholders adopted the below resolutions.Resolution regarding adoption of the profit and loss account and balance sheet for the company and the group as well as resolutions in respect of appropriation of profits and discharge from liability The meeting resolved to adopt the profit and loss account and balance sheet for the group and the Company included in the annual report. The meeting resolved to allocate the profit for the year in accordance with the board of directors’ proposal, i.e. SEK

Notice to attend the annual general meeting of Heliospectra

The shareholders of Heliospectra AB (publ), company reg. no 556695-2205, are hereby given notice to attend the Annual General Meeting to be held on Tuesday, 14 June 2016 at 3 PM in the company's offices at Frans Perssons Väg 6 in Gothenburg. Registration for the annual general meeting begins at 2 PM.Notice of intention to participateAny shareholder wishing to participate at the Annual General Meeting must: - be entered in the share register maintained by Euroclear Sweden AB (previously VPC AB) as per Wednesday, 8 June 2016; and - provide notice of intention to attend to the company

Successful first issue under the new Green MTN programme

On 13 May 2016, Fabege made its first issue under the recently established Green MTN programme. Fabege has issued 600 SEKm of two year bonds with a variable interest rate of 3M Stibor plus 130 bps. Handelsbanken.acted as sole bookrunner for the transaction. By establishing an MTN programme with specific terms and conditions relating to sustainability and environment, Fabege launched a new green financing facility totalling 2,000 SEKm in April.  -  We are very happy about the great interest shown in this first issue under our new Green MTN programme and have noted strong demand from

Precise Biometrics signs license agreement with Oberthur Technologies for secure fingerprint recognition in eSE

Precise Biometrics, the leader in fingerprint software, has entered an agreement with Oberthur Technologies (OT), a leading global provider of embedded security software, products, services and solutions, for licensing of Precise BioMatch™ Embedded. The integration of  Precise Biometrics’ leading fingerprint recognition solution in PEARL by OT®, the most advanced multi-application embedded secure element (eSE) on the market for mobile, M2M and IoT devices, brings an additional layer of security to biometric authentication and enables easy deployment of secure services using fingerprint

Magnolia Bostad reports on the first quarter of 2016

The Company is reporting an operating profit/loss for the period of SEK 99.5 million (146.1). Profit/loss after tax was SEK 85.8 million (138.7), which adjusted for items affecting comparability is the company’s best result to date.– The first months of 2016 were characterized by strong sales and intensive business activity, says Fredrik Lidjan, CEO of Magnolia Bostad. I am also pleased to announce that we have successfully conducted a bond issue of SEK 600 million. The first quarter in brief: · Operating profit/loss: SEK 99.5 (146.1) million · Profit/loss after tax: SEK 85.8 (

Leeds St James acquires eight Elekta linear accelerators for advanced cancer treatment

LEEDS, UK, May 17, 2016 – Leeds Cancer Centre, one of the largest providers of cancer care in the UK, will upgrade its existing treatment equipment with eight Elekta (EKTA-B.ST) Versa HD™  linear accelerators. This replacement will bring world-class treatment to the center, and secure its leading position within cancer treatment in the country.Dr. Viv Cosgrove, Head of Radiotherapy Physics at Leeds Cancer Centre, says: “The new linear accelerators are able to deliver improvements in treatment accuracy for patients. This will help us increase the use of high

Camurus Interim Report January-March 2016

“We are in a strong growth phase and on track to deliver on all our key objectives for this year.”Business highlights first quarter 2016 · Recruitment goals reached in two Phase 3 trials of CAM2038 for opioid dependence treatment. · Start of Phase 2 study of CAM2038 in patients with chronic pain. · Completion of Phase 2 study of CAM2029 in two patient groups with acromegaly or neuroendocrine tumors. · Completion of Phase 1 study of CAM4071 in healthy volunteers. · Clinical development supporting toxicology studies initiated for two new product candidates after completed

Componenta Corporation’s issuance of convertible capital loan of EUR 40 million

Componenta Corporation Stock Exchange Release 17.5.2016 at 8.00 Componenta Corporation has on 11 May 2016 announced the acceptance of subscriptions for a convertible capital loan of EUR 40 million and discharge of secured bank loans and a secured bond. Componenta Corporation has on 16 May 2016 issued a convertible capital loan of EUR 40 million and discharged of secured bank loans and a secured bond. As a result of the arrangement, the amount of the company’s secured debt has decreased by more than EUR 72 million.   Helsinki, 17 May 2016 COMPONENTA CORPORATION Harri

There are no items matching the current filter
There are no more items matching the current filter
Back to top